Published in J Chromatogr on February 11, 1983
Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension. Br J Clin Pharmacol (1984) 0.97
Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. Br J Clin Pharmacol (1987) 0.90
Ketanserin pharmacokinetics in patients with renal failure. Br J Clin Pharmacol (1990) 0.75
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest (1975) 4.65
Delayed clearance of diazepam due to cimetidine. N Engl J Med (1980) 3.45
Midazolam kinetics. Clin Pharmacol Ther (1981) 2.88
Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr (1987) 2.76
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Telomere length in different tissues of elderly patients. Mech Ageing Dev (2000) 2.45
Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med (1980) 2.39
The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 2.27
Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol (2001) 1.88
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1993) 1.71
Affinity chromatographic isolation of the periplasmic maltose binding protein of Escherichia coli. FEBS Lett (1978) 1.71
Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol (1983) 1.69
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther (1993) 1.66
Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother (1986) 1.60
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.57
Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther (1982) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol (1989) 1.49
Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) (1983) 1.47
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol (2000) 1.43
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet (1985) 1.41
Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol Ther (1991) 1.39
Low-dose lisinopril in normotensive men with idiopathic oligospermia and infertility: a 5-year randomized, controlled, crossover pilot study. Clin Pharmacol Ther (2012) 1.39
Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol (1976) 1.36
Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. Br J Clin Pharmacol (1990) 1.35
Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol (1986) 1.34
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther (1976) 1.28
Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter (1998) 1.27
Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol (1980) 1.26
Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet (1994) 1.25
The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22
Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother (1993) 1.21
Cimetidine/diazepam interaction. Lancet (1979) 1.19
Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) (1995) 1.18
Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol (1989) 1.18
The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry (1994) 1.17
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet (1992) 1.17
Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol (1981) 1.16
Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14
Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol (1985) 1.14
Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13
Eye disease in an onchocerciasis-endemic area of the forest-savanna mosaic region of Nigeria. Bull World Health Organ (1996) 1.13
Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease. Trans R Soc Trop Med Hyg (1982) 1.13
Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. Eur J Clin Pharmacol (1984) 1.12
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol (1996) 1.11
The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol (1992) 1.10
Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos (1994) 1.09
Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther (1977) 1.08
Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother (1997) 1.07
Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther (1977) 1.07
Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr (1981) 1.07
A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittelforschung (1985) 1.06
Analytical information is mandatory for pharmacokinetic papers. Clin Pharmacol Ther (1996) 1.05
Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology (1989) 1.00
Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol (2001) 1.00
How do rural households perceive and prioritise malaria and mosquito nets? A study in five communities of Nigeria. Public Health (2000) 1.00
Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol (1992) 1.00
Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. Br J Clin Pharmacol (1985) 0.99
Altered elimination of desmethyldiazepam in the elderly. Br J Clin Pharmacol (1979) 0.99
Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg (1997) 0.98
Alfentanil kinetics in the elderly. Clin Pharmacol Ther (1984) 0.98
Antipyrine metabolism is not affected by terbinafine, a new antifungal agent. Eur J Clin Pharmacol (1989) 0.98
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter (2002) 0.97
Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther (1982) 0.97
Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol (1988) 0.97
Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur J Clin Pharmacol (1985) 0.97
Oroileal transit of slow release 5-aminosalicylic acid. Gut (1993) 0.96
Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet (2001) 0.96
Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin Pharmacokinet (1976) 0.95
Effects of diclofenac on lithium kinetics. Clin Pharmacol Ther (1981) 0.95
Telomeres in neonates: new insights in fetal hematopoiesis. Pediatr Res (2001) 0.94
Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology (Berl) (1986) 0.94
Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet (1996) 0.93
No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet (1988) 0.93
Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis? Ther Drug Monit (1980) 0.93
A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol (1998) 0.92
Intravenous benzodiazepines as anaesthetic agents: pharmacokinetics and clinical consequences. Acta Anaesthesiol Scand (1982) 0.92
Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? Br J Clin Pharmacol (1986) 0.92
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res (2000) 0.92
Indomethacin but not aspirin increases plasma lithium ion levels. Arch Gen Psychiatry (1983) 0.91
Ivermectin levels in human breastmilk. Eur J Clin Pharmacol (1993) 0.91
Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies. Ther Drug Monit (1993) 0.91
Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol (1998) 0.90
High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr (1979) 0.90
Clinical efficacy of oral 5-aminosalicylic acid in the treatment of inflammatory bowel disease. Am J Gastroenterol (1985) 0.90
Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther (1981) 0.90
Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology (1995) 0.90
Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet (1993) 0.89
Is N-acetylation of 5-aminosalicylic acid reversible in man? Br J Clin Pharmacol (1984) 0.89
Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther (1998) 0.89
Does pH 6 beta-galactosidase activity indicate cell senescence? Mech Ageing Dev (1999) 0.89
Chronopharmacokinetic study with prolonged infusion of midazolam. Clin Pharmacokinet (1985) 0.89